The Role of suPAR Biomarker in Blood Samples of Breast Cancer Patients During and Post Doxorubicin Chemotherapy: Causative vs. Predictor
CompletedOBSERVATIONAL
Enrollment
42
Participants
Timeline
Start Date
January 17, 2017
Primary Completion Date
July 6, 2020
Study Completion Date
July 6, 2020
Conditions
Doxorubicin Adverse ReactionCardiomyopathies, SecondaryBreast Cancer
Trial Locations (2)
60304
Rush Oak Park Hospital, Oak Park
60612
Rush University Medical Center, Chicago
All Listed Sponsors
lead
Rush University Medical Center
OTHER
NCT03505164 - The Role of suPAR Biomarker in Blood Samples of Breast Cancer Patients During and Post Doxorubicin Chemotherapy: Causative vs. Predictor | Biotech Hunter | Biotech Hunter